775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
Title:
775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
Author:
D'Haens, Geert R. Colombel, Jean Frederic Bossuyt, Peter Danese, Silvio Lim, Allen Lindsay, James Hisamatsu, Tadakazu Ran, Zhihua Rubin, David T. Neimark, Ezequiel Huang, Bidan Liao, Xiaomei Berg, Sofie Duan, W. Rachel Wallace, Kori Sandborn, William J.